Patents Assigned to CONSTELLATION PHARMACEUTICALS, INC.
  • Patent number: 11459315
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compostions thereof, which are useful for treating a variety of conditions associated with methyl modifying enzymes.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: October 4, 2022
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Jehrod B. Brenneman, Alexandre Côté, Victor S. Gehling, Avinash Khanna, Julian R. Levell, Ludivine Moine
  • Patent number: 11414384
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: August 16, 2022
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Jonathan E. Wilson, Julian R. Levell
  • Publication number: 20220127265
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • Patent number: 11274095
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: March 15, 2022
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
  • Patent number: 11274090
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone acetyltransferase (HAT).
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: March 15, 2022
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Jonathan E. Wilson, Francois Brucelle, Julian R. Levell
  • Patent number: 11247989
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: February 15, 2022
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • Patent number: 11168070
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: November 9, 2021
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • Patent number: 11013718
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: May 25, 2021
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • Patent number: 10918646
    Abstract: The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: February 16, 2021
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Adrian Senderowicz, Michael Cooper
  • Publication number: 20200399244
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R—R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: May 28, 2020
    Publication date: December 24, 2020
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • Patent number: 10696655
    Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: June 30, 2020
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
  • Patent number: 10689371
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: June 23, 2020
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
  • Publication number: 20200069677
    Abstract: Provided herein are methods of treating cancers characterized by a high expression of GFIIB, comprising administering a therapeutically effective amount of a KDMIA inhibitor.
    Type: Application
    Filed: December 8, 2017
    Publication date: March 5, 2020
    Applicants: Constellation Pharmaceuticals, Inc., Constellation Pharmaceuticals, Inc.
    Inventors: John McGrath, Patrick Trojer
  • Patent number: 10577350
    Abstract: The present disclosure relates to a crystalline Forms A, B, and C of (R)—N-((4-methoxy-6-methyl-2-oxo-1,2-di-hydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide, each of which are useful as modulators the activity of histone methyl modifying enzymes. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: March 3, 2020
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Alisha Arrigo, Donald Corson, Victor S. Gehling, Bruno Patrice Haché, Jean-Christophe Harmange, Jonathan Lane
  • Patent number: 10526287
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 7, 2020
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Rishi G. Vaswani
  • Patent number: 10517849
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 31, 2019
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • Patent number: 10457640
    Abstract: Provided herein are synthetic methods for the preparation of EZH2 inhibitors.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: October 29, 2019
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Rishi G. Vaswani, Michael Charles Hewitt
  • Publication number: 20190274998
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Application
    Filed: October 26, 2017
    Publication date: September 12, 2019
    Applicant: Constellation Pharmaceuticals, Inc.
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • Publication number: 20190241558
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: November 21, 2018
    Publication date: August 8, 2019
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • Patent number: 10358437
    Abstract: The present invention relates to methods for treating PCAF mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: July 23, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Alexandre Cote, Terry Crawford, Martin Duplessis, Andrew Charles Good, Yves LeBlanc, Steven Magnuson, Christopher G. Nasveschuk, Richard Pastor, F. Anthony Romero, Alexander M. Taylor